on Mipomersen to the FDA’s Endocrinologic and Metabolic Drugs Advisory
October 18, 2012
View as PDF.
View press release
The Food and Drug Administration (FDA) should not approve the proposed cholesterol drug mipomersen because the study supporting approval was unethical and withheld an effective therapy from patients with a rare disease, while the drug itself causes a plethora of serious side effects.